Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Commentary

Comment on Zhuang YF et al.: Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis

Authors: Jinlong Ma, Ling Fang, Feng Zhang

Published in: Tumor Biology | Issue 9/2014

Login to get access

Excerpt

To the Editor: …
Literature
1.
Zhuang YF, We MY. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumor Biol. 2014;35(3):1745–9.CrossRef
2.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralCrossRefPubMed
3.
Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572–7.PubMed
4.
Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005;28:755–60.PubMed
5.
Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53:1035–9.CrossRefPubMed
6.
Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, et al. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2011;28:649–53.CrossRefPubMed
7.
Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011;117:4925–38.PubMedCentralCrossRefPubMed
8.
Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S, et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop. 2012;36:2315–21.PubMedCentralCrossRefPubMed
9.
Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res. 2006;448:193–8.CrossRefPubMed
10.
Chen GL, Lin HB, Wu XW, Li RY, Chen XH. The correlation between the level of serum VEGF and BFGF with metastasis and prognosis of osteosarcoma. Chin J Cell Mol Immunol. 2011;27:1343–5.
11.
Lugowska I, Wozniak W, Klepacka T, Michalak E, Szamotulska K. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer. 2011;57:63–8.CrossRefPubMed
Metadata
Title
Comment on Zhuang YF et al.: Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis
Authors
Jinlong Ma
Ling Fang
Feng Zhang
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2468-x

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis

Research Article

No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis

Research Article

RETRACTED ARTICLE: Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis

Research Article

Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies

Research Article

Increased MTHFD2 expression is associated with poor prognosis in breast cancer

Research Article

An increased risk of ovarian cancer associated with polymorphism in BRCC5 gene in Caucasian populations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits